Arcellx (ACLX) Other Non-Current Assets (2021 - 2025)
Arcellx (ACLX) recorded quarterly Other Non-Current Assets of $3.0 million in Q4 2025, up 814.29% quarter-over-quarter from $329000.0 in Q3 2025, and up 179.29% on a YoY basis from $1.1 million in Q4 2024.
Arcellx (ACLX) Other Non-Current Assets (2021 - 2025) Analysis & Trends
Arcellx's Other Non-Current Assets history runs 5 years deep, the most recent figure standing at $3.0 million for Q4 2025.
- In Q4 2025, Other Non-Current Assets rose 179.29% year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $3.0 million (up 179.29% YoY), while the FY2025 annual figure was $3.0 million, up 179.29% from the prior year.
- Other Non-Current Assets was $3.0 million for Q4 2025 at Arcellx, up from $329000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $9.4 million in Q4 2023 to a low of $199000.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $2.6 million across 5 years, with a median of $2.5 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets jumped 1156.78% in 2023, then sank 88.49% in 2024.
- A 5-year view of Other Non-Current Assets shows it stood at $3.2 million in 2021, then decreased by 21.15% to $2.5 million in 2022, then jumped by 274.09% to $9.4 million in 2023, then tumbled by 88.49% to $1.1 million in 2024, then surged by 179.29% to $3.0 million in 2025.
- The last three Other Non-Current Assets figures came in at $3.0 million (Q4 2025), $329000.0 (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 3.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.01 Mn |
| Sep 30, 2025 | 329,000.00 |
| Jun 30, 2025 | 2.42 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 1.08 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.22 Mn |
| Mar 31, 2024 | 2.42 Mn |
| Dec 31, 2023 | 9.36 Mn |
| Sep 30, 2023 | 4.93 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 2.50 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Mar 31, 2022 | 199,000.00 |
| Dec 31, 2021 | 3.17 Mn |